JP2013516475A - Ｄｐ２アンタゴニストおよびその使用 - Google Patents

Ｄｐ２アンタゴニストおよびその使用 Download PDF

Info

Publication number
JP2013516475A
JP2013516475A JP2012548102A JP2012548102A JP2013516475A JP 2013516475 A JP2013516475 A JP 2013516475A JP 2012548102 A JP2012548102 A JP 2012548102A JP 2012548102 A JP2012548102 A JP 2012548102A JP 2013516475 A JP2013516475 A JP 2013516475A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
disease
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012548102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516475A5 (OSRAM
Inventor
ブリテイン，ジェイソン，エドワード
キング，クリストファー，デイビッド
スターンズ，ブライアン，アンドリュー
Original Assignee
アミラ ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アミラ ファーマシューティカルズ，インク． filed Critical アミラ ファーマシューティカルズ，インク．
Publication of JP2013516475A publication Critical patent/JP2013516475A/ja
Publication of JP2013516475A5 publication Critical patent/JP2013516475A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012548102A 2010-01-06 2011-01-05 Ｄｐ２アンタゴニストおよびその使用 Pending JP2013516475A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29280710P 2010-01-06 2010-01-06
US61/292,807 2010-01-06
PCT/US2011/020264 WO2011085033A2 (en) 2010-01-06 2011-01-05 Dp2 antagonist and uses thereof

Publications (2)

Publication Number Publication Date
JP2013516475A true JP2013516475A (ja) 2013-05-13
JP2013516475A5 JP2013516475A5 (OSRAM) 2014-01-30

Family

ID=44306127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012548102A Pending JP2013516475A (ja) 2010-01-06 2011-01-05 Ｄｐ２アンタゴニストおよびその使用

Country Status (13)

Country Link
US (1) US9688624B2 (OSRAM)
EP (1) EP2521713A4 (OSRAM)
JP (1) JP2013516475A (OSRAM)
KR (1) KR20120115989A (OSRAM)
CN (1) CN102812000A (OSRAM)
AU (1) AU2011203649A1 (OSRAM)
CA (1) CA2782085A1 (OSRAM)
EA (1) EA201270653A1 (OSRAM)
IL (1) IL219987A0 (OSRAM)
MX (1) MX2012007927A (OSRAM)
PH (1) PH12012501349A1 (OSRAM)
SG (1) SG182398A1 (OSRAM)
WO (1) WO2011085033A2 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010014172A (es) * 2008-07-03 2011-02-22 Amira Pharmaceuticals Inc Antagonistas de receptores de prostaglandina d2.
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
JP2015500326A (ja) 2011-12-16 2015-01-05 アトピックス テラピューティクス リミテッド 好酸球性食道炎の治療のためのｃｒｔｈ２拮抗薬およびプロトンポンプ阻害薬の組み合わせ
JP6193968B2 (ja) * 2012-03-21 2017-09-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 発毛を調節するための組成物および方法
CN103830194A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗固体分散体及含有其的药物组合物
US12059695B2 (en) * 2021-09-16 2024-08-13 Caterpillar Paving Products Inc. Fluid spray system timing control

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508318A (ja) * 2001-09-14 2005-03-31 トゥラリック インコーポレーテッド 連結ビアリール化合物
JP2006516143A (ja) * 2002-12-20 2006-06-22 トゥラリック インコーポレイテッド 喘息及びアレルギー性炎症モジュレーター
WO2007068894A2 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
JP2008505874A (ja) * 2004-07-08 2008-02-28 アストラゼネカ・アクチエボラーグ 呼吸器疾患処置用の置換酸
WO2008024746A1 (en) * 2006-08-21 2008-02-28 Array Biopharma, Inc. 4-substituted phenoxyphenylacetic acid derivatives
JP2013500978A (ja) * 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの眼の医薬組成物
JP5531370B2 (ja) * 2008-07-03 2014-06-25 パンミラ ファーマシューティカルズ，エルエルシー． プロスタグランジンｄ２受容体のアンタゴニスト

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239084A (en) 1990-06-29 1993-08-24 Hoffmann-La Roche Inc. Substituted aminoalkyl biphenyl compounds
US5827868A (en) 1991-10-07 1998-10-27 E. R. Squibb & Sons, Inc. Prostaglandin analogs
US5334598A (en) 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5565485A (en) 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5391566A (en) 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
DE19601782A1 (de) 1996-01-19 1997-07-24 Merck Patent Gmbh Chinolin-2-(1H)one
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6429213B1 (en) 1998-06-17 2002-08-06 Bristol Myers Squibb Pharma Co Cyclic hydroxamic acids as metalloproteinase inhibitors
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
CA2371308A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
DE19937537A1 (de) 1999-08-09 2001-03-08 Gruenenthal Gmbh Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate
JP3486408B2 (ja) 1999-08-23 2004-01-13 株式会社ビー・エム・エル 物質のヒトプロスタグランジンｄ２受容体に対する性質の同定方法
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EP1395590B1 (en) 2001-05-23 2006-09-27 Merck Frosst Canada & Co. Dihydropyrrolo¬1,2-a|indole and tetrahydropyrido¬1,2-a|indole derivatives as prostaglandin d2 receptor antagonists
US20030114457A1 (en) 2001-07-09 2003-06-19 Axys Pharmaceuticals, Inc. 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
ATE479686T1 (de) 2002-10-30 2010-09-15 Merck Frosst Canada Ltd Pyridopyrrolizin- und pyridoindolizinderivate
JP2004182657A (ja) 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
RU2006109108A (ru) 2003-10-14 2007-11-20 Оксаген Лимитед (GB) Соединения, обладающие активностью антагонистов crth2 рецепторов
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
WO2005051373A1 (ja) 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited 受容体機能調節剤
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CN1942428A (zh) 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
AU2005274277A1 (en) 2004-08-17 2006-02-23 Galderma Research & Development, S.N.C. Novel biaromatic compounds which activate receptors of PPAR type and their use in cosmetic or pharmaceutical compositions
AU2005286717A1 (en) 2004-09-21 2006-03-30 Wyeth Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
EA200700712A1 (ru) 2004-09-21 2008-02-28 Эсерсис, Инк. Производные индолуксусной кислоты, способ получения таких производных (варианты), фармацевтическая композиция, набор на их основе, способ ингибирования связывания эндогенных лигандов и способ лечения заболеваний и расстройств, восприимчивых к ингибированию связывания эндогенных лигандов с рецептором crth-2
WO2006052798A2 (en) 2004-11-08 2006-05-18 Merck & Co., Inc. Method of treating pathological blushing
AR053784A1 (es) 2004-11-23 2007-05-23 Pfizer Prod Inc Compuestos y derivados tetrazolicos de dibencil amina. composiciones farmaceuticas.
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
DK1976828T3 (en) 2005-12-29 2017-03-06 Celtaxsys Inc DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE
MX2008015638A (es) * 2006-06-09 2009-01-09 Icos Corp Acidos fenil aceticos sustituidos como antagonistas de dp-2.
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
KR101171480B1 (ko) 2007-07-02 2012-08-07 에프. 호프만-라 로슈 아게 Ｃｃｒ-2 수용체 길항제로서의 이미다졸 유도체
EP2205583A2 (en) 2007-10-01 2010-07-14 F. Hoffmann-Roche AG N-heterocyclic biaryl carboxamides as ccr receptor antagonists
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
MX2010007833A (es) 2008-01-18 2010-08-11 Oxagen Ltd Compuestos que tienen actividad antagonista de crth2.
WO2009099902A1 (en) 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
UA98839C2 (en) 2008-02-01 2012-06-25 Панмира Фармасьютикалз, Ллк. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
JP2011518130A (ja) * 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US20100173313A1 (en) 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
CN102596193A (zh) 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗的皮肤调配物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508318A (ja) * 2001-09-14 2005-03-31 トゥラリック インコーポレーテッド 連結ビアリール化合物
JP2006516143A (ja) * 2002-12-20 2006-06-22 トゥラリック インコーポレイテッド 喘息及びアレルギー性炎症モジュレーター
JP2008505874A (ja) * 2004-07-08 2008-02-28 アストラゼネカ・アクチエボラーグ 呼吸器疾患処置用の置換酸
WO2007068894A2 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
WO2008024746A1 (en) * 2006-08-21 2008-02-28 Array Biopharma, Inc. 4-substituted phenoxyphenylacetic acid derivatives
JP5531370B2 (ja) * 2008-07-03 2014-06-25 パンミラ ファーマシューティカルズ，エルエルシー． プロスタグランジンｄ２受容体のアンタゴニスト
JP2013500978A (ja) * 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの眼の医薬組成物

Also Published As

Publication number Publication date
EP2521713A4 (en) 2013-10-02
AU2011203649A1 (en) 2012-06-14
CA2782085A1 (en) 2011-07-14
IL219987A0 (en) 2012-07-31
EA201270653A1 (ru) 2012-11-30
US20130053444A1 (en) 2013-02-28
PH12012501349A1 (en) 2013-01-14
SG182398A1 (en) 2012-08-30
KR20120115989A (ko) 2012-10-19
WO2011085033A3 (en) 2011-11-17
US9688624B2 (en) 2017-06-27
MX2012007927A (es) 2012-08-15
WO2011085033A2 (en) 2011-07-14
EP2521713A2 (en) 2012-11-14
CN102812000A (zh) 2012-12-05

Similar Documents

Publication Publication Date Title
US9572785B2 (en) DP2 antagonist and uses thereof
JP2013501052A6 (ja) Ｄｐ２アンタゴニストおよびその用途
CA2724726C (en) 5-lipoxygenase-activating protein inhibitor
RU2744460C2 (ru) Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
US8383654B2 (en) Heterocyclic antagonists of prostaglandin D2 receptors
JP2013516475A (ja) Ｄｐ２アンタゴニストおよびその使用
JP2011521912A (ja) プロスタグランジンｄ２受容体の三環式アンタゴニスト
WO2012069202A1 (en) Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
EP3510023B1 (en) Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
JP2011500846A (ja) ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）阻害剤
US11998553B2 (en) Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
TW200901986A (en) New combination
TW202342035A (zh) 醫藥乾粉吸入配製物
TW202342012A (zh) 製備用作醫藥活性化合物的（５ｓ）－｛［２－（４－羧基苯基）乙基］［２－（２－｛［３－氯－４＇－（三氟甲基）聯苯－４－基］甲氧基｝苯基）乙基］胺基｝－５，６，７，８－四氫喹啉－２－羧酸及其結晶形式之方法
CN101351495A (zh) 脂肪酸酰胺水解酶抑制剂
CN102202665A (zh) 包含毒蕈碱性受体拮抗剂和另一种活性成分的药物产品
KR20110044948A (ko) 5-리폭시게나아제 활성화 단백질 억제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150603